DE1620131C3 - i-Methyl-2-square bracket on 2- (3-methyl-2-thynyl) -vinyl square bracket to Delta to the power of 2 -tetrahydropyrimidine - Google Patents

Description

CH,

as well as its pharmaceutically acceptable acid storage salts and resin adsorbates.

2. Process for the preparation of the compound according to claim 1 and their pharmaceutically acceptable ones Acid addition salts and resin adsorbates, characterized in that one in per se known way

(A) 3- [(3 - methyl) -2 - thienyl] acrylonitrile with N-methyltrimethylenediamine tosylate or

(b) the imino ether of formula II

NH

CH = CH -CO- (CH ₂ )., - SO ₁ H

(U)

with N-methyl-trimethylenediamine or

c) an Iminoiitherhydrochlorid of the general Formula III

NH

I! x -

OR ₁ • HCl

CH = CH
S (III)

or an ester of the general formula IV

COOR ₁ (IV)

in which R ₁ denotes a low molecular weight alkyl radical, with N-methyl-trimethylenediamine or

(d) 3 - [(3-methyl) -2-thienyl] acrylonitrile in the presence of hydrogen sulfide or phosphorus pentasulfide Reacts with N-methyltrimethylenediamine and any salts obtained in the free Base or by anion exchange in other salts or by cation exchange in resin adsorbates transferred or the free base obtained converts into acid addition salts.

3. anthelmintics, consisting of a compound according to claim 1 or one of their pharmaceuticals compatible acid addition salts or resin adsorbates together with the usual auxiliary and Carriers.

CH = CH - <:

CU,

and its pharmaceutically acceptable acid addition salts and resin adsorbates, a process for preparing this compound and a worming agent which consists of this compound and customary auxiliaries and carriers.

Worm disease, d. H. the infestation of the human and animal body by different types of Parasites are possibly the most common and common disease these days. Although the importance of this disease from an economic point of view has become widespread Research into new and more effective anthelmintics has led to the present day Days did not develop countermeasures entirely satisfactorily for one or more reasons; so these means show z. B. a low therapeutic index, a low specificity of the Effect, they cause high costs, are not very active, and their scope is limited.

It has been found that the compound of the present invention (cis and trans isomers) and their pharmaceutically compatible acid addition salts and resin adsorbates surprisingly in the treatment worm diseases in animals and humans, e.g. B. in therapeutic and prophylactic Treatment, when administered by oral or parenteral route Ways are extraordinarily effective.

The non-toxic acid addition salts that can be used are water-soluble and water-insoluble salts, e.g. B. the chlorohydrate, hydrobromide, phosphate, nitrate, sulfate, acetate, citrate, Gluconate, benzoate, propionate, butyrate, sulfosalicylate, maleate, laurate, malate, fumarate, succinate, oxalate, Tartrate, amsonate (4,4'-diaminostilbene-2,2'-disulfonate), pamoate (l, l'-methylene-bis-2-hydroxy-3-naphthoate), Stearate, 2-hydroxy-3-naphthoate, hexafluorophosphate, toluene-p-sulfonate, the suramine salt and Resin adsorbates.

The compound of the invention is against both the ripened and the unripe forms of Effective against worms of the families Ancylostomidae, Strongylodoidae and Trichostrongylidae. She is special against gastrointestinal parasites of humans, ruminants (e.g. sheep, cattle, goats) and non-ruminants, e.g. B. dogs, cats, horses and pigs.

The responsiveness of these groups of parasites to chemotherapeutic agents is examined, by selecting a parasite infestation generated for experimental purposes of a test animal whose The relationship between the host and the parasite is similar to that between such parasites and pets. Such there is a relationship between Nematospiroides dubius and mice infected for experimental purposes, between Nippostrongylus muris and rats and mice infected for experimental purposes. The attempt

with N. dubius and experimentally infected mice is carried out by collecting the feces of an infected mouse and suspending them in moist charcoal. Small pellets are made and incubated at room temperature for 4 to 5 days, until the egg cells, brood and larvae are developed. The larvae are then collected and used for Vaccination of healthy mice used. It was determined, that inoculation of 40 larvae per mouse resulted in successful infection; d. that is after a development period of 14 days, about 30 adult worms had formed. Usual wormer products proved to be ineffective against vaccination of this magnitude.

The experiment with N. muris consists in collecting the feces of infected rats and placing them in fecal cultures in the same way as for N. dubius. The cultures (animal charcoal pellets) are Incubated for 7 days at 26 ° C. The larvae are then collected and used to vaccinate healthy mice used. Weaned by inoculating 500 larvae and 1.25 mg hydrocortisone acetate (subcutaneously) into young Mice are successfully infected.

S. obvelata, the pinworm of rats and mice, is naturally left to its own devices obtained within the establishment colony, so that practically all mice infected with N. dubius and N. muris can also be infected with S. obvelata.

The compound of the invention and its pharmaceutically acceptable acid addition salts and Resin adsorbates can be administered orally or parenterally. Subcutaneous and intramuscular injections are the preferred methods of parenteral injection. Suitable carriers for parenteral Injection are aqueous vehicles such as water, isotonic salt solutions, isotonic dextrose solutions, Ringer's solution, or non-aqueous vehicles such as fatty oils of vegetable origin, e.g. B. Cottonseed Oil, Peanut oil, grain oil, sesame oil. In addition, preparations can be made for the later preparation of solutions prior to administration are suitable. Such preparations can liquid diluents, e.g. B. propylene glycol, diethyl carbonate, glycerin, sorbitol, buffers and local anesthetics and inorganic salts.

Oral administration can take place in various ways, for example by adding to the Feed, with dosage units, e.g. B. capsules, tablets, liquid mixtures and solutions. To the Drinking dilute solutions can be made. Also wettable powder that is the active ingredient can be added to the drinking water.

Larger pills and capsules are also used for therapeutic treatment of animals.

The trans compound according to the invention is photosensitive, especially in solution, and converts into various products including the cis isomer around. It must therefore be protected from light, e.g. B. by storage in the dark or in brown Bottles or in dark capsules.

The compound according to the invention is produced by the methods mentioned in claim 2, which are known per se won.

The starting compound mentioned under b) is obtained by reacting (3-methyl-2-thicnyl) acrylamide with 1,3-propane sultone (Ried and Schmitt, Ann. 676, 114 [1964]). The thus obtained Connection has the trans configuration. The cis isomer is obtained by irradiating the trans isomer.

The tosylate and hydrochloride obtained as described can be obtained by simple neutralization of the acid portion of the salt can easily be converted into the free base by aqueous Sodium or potassium hydroxide, and the water-insoluble free base can be mechanically or by solvent extraction with a suitable water-immiscible solvent, such as ethyl acetate, can be isolated. The free base that has been isolated by means of the solvent can

'5 optionally by recrystallization from suitable Solvents or vacuum distillation. You can also use the free base Neutralize an acidic salt with sodium methylate in methanol, using the base known methods wins. Other acid addition salts can easily be obtained by the free base in a suitable solvent, e.g. B. acetone, water, a low molecular weight aliphatic Alcohol (ethanol, isopropanol), which contains the desired acid, dissolves or to which the desired Acid is given afterwards. The salts are filtered off with a non-solvent precipitated or by evaporation of the solvent, in the case of aqueous solutions, also by lyophilization won. In this way the following salts can be produced: sulfate, nitrate, phosphate, Acetate, propionate, butyrate, citrate, gluconate, benzoate, pamoate, amsonate, tartrate, 3-2-hydroxy-2-naphthoate and suifosalycilate. In the case of dibasic acids,

z. B. Pamoin and Amsonic acid, a ratio of acid to base of 1: 2 (molar ratio) is used, to achieve the appropriate salt. The inorganic polybasic acids are generally used applied in a molar ratio of 1: 1 with the desired base.

The tosylate salt of the cyclic amidine obtained can be converted into the corresponding chlorohydrate by percolation a methanolic solution of the tosylate through the chloride form of an anion exchange resin be transferred. Other acid addition salts can also be obtained in this way will.

Resin adsorbates of the cyclic amidine according to the invention are expediently made by slurry an aqueous solution of a water-soluble salt of the cyclic amidine with a suspension the sodium form of a cation exchange resin during one to adsorb the compound through the resin produced for a sufficient period of time. Suitable resins are strongly acidic cation exchange resins, z. B. sulfonated styrene-divinylbenzene polymers that are crosslinked to varying degrees.

The 3- (3-methyl-2-thienyl) -acrylonitrile is obtained by a Knoevenagel condensation of 3-methyl-thiophene-2-carboxaldehyde with cyanoacetic acid in the presence of a catalyst. Catalysts are

z. B. ammonia, primary or secondary amines, pyridine, piperidine, ammonium acetate-pyridine.

The effectiveness of l-methyl-2- [2- (3-methyl-2-

thienyl) - vinyl] - I ² - tetrahydropyrimidine chlorohydrate as an agent against worm diseases was carried out using mice infected in the laboratory with Nematospiroides dubius and in the laboratory with nip-

postrongylus muris infected rats. The foliage events were received:

dose

1 x 250 mg / kg reduction
of the worm
infested N. dubius 1 ■ 125 mg kg 100 N. dubius 1 x 62.5 mg / kg 100 N. dubius 1 -31.25 mg kg 100 N. dubius 1-7.8 mg kg 100 N. dubius 1 x 3.5 mg kg 100 N. dubius 1 · 1.25 m »/ ku 100 N. dubius 93

The effectiveness of l-methyl-2- [2- (3-methyl-2-thicnyl) vinyl] - ^ -tctrahydropyrimidintarlrat against the migratory phases of Ascaris suum in pigs was determined as follows.

Nine 4 week old pigs were divided into three Divided into groups of 3 pigs each and treated in the following way.

Group 1 - not infected, not treated with drugs,

Group 2 - infected, not treated with medication,

Group 3 - infected, treated with drug.

The active substance was administered in Group 3 in the basic ration in an amount of 50 g Drug per ton of ration starting 2 days of complete infection. The piglets were on the 3rd and 4th day artificially infected by giving them 100,000 embryo-containing eggs per day with the wet food (per piglet) administered. Group 2 piglets were infected in the same way. The piglets of the Group 3 received the medicated feed ad libitum as during the pre-infection period for a total duration of 10 days.

All animals were slaughtered 7 days after infection, and the livers and lungs were sorted according to characteristic damage and number of larvae examined.

The drug was found to be highly effective in protecting piglets against Ascaris suum infection. the infected, untreated medication

ίο animals started beating, coughing and were Without appetite and exhausted, her livers and lungs were covered with innumerable punctiform damage and showed punctiform bleeding. The infected medicated animals showed during

■ 5 of the experiment no abnormal utterances. your Livers showed some damage. However, similar patch-like damage did not appear in those either infected and unmedicated treat animals, indicating that they are to some extent had a natural Ascaris suum infection.

There was also a reduction in the number of

Larvae observed in the lungs of up to 98%.

This was determined by removing a 10g sample from both lungs, the samples at 37C Digested overnight in acidified pepsin and the resulting liquid with the aid of a binocular microscope examined for the presence of larvae.

From BE-PS 6 58 987 this is also used as a worming agent useful 2-methyl-2- [2- (2-thienyl) -vinyIJ-

l ² -tctra-hydropyrimidine known. It was then to be expected that the compound according to the invention could be effective in the same direction. However, it was not to be expected that the compound according to the invention would be many times more effective.

In the following table the effectiveness of the compound according to the invention is compared with the effectiveness of 1-methyl-2- [2- (2-thienyl) vinyl] - ^ -tetrahydropyrimidine compared to Nematospiroides dubius in mice, ankylostoma (hookworm) and Ascaris in dogs and gastrointestinal nematodes in sheep. This comparison shows that surprisingly greater effectiveness of the compound of the invention in all cases.

Comparison of the effectiveness of the compound according to the invention and of l-methyl-2- [2- (2-thienyl) vinyl] -l ² -tetrahydropyrimidine against Nematospiroides dubius in mice, ankylostoma and Ascaris in dogs and gastrointestinal nematodes in sheep

Miiu se

LD ₅₀ . oral dogs

(mg / kg) (mg / kg) (mg / kg) (mg / kg |

Sheep

MTD ¹ ) ED _{<J (1st} ED «,,. EU ₁₁ ,. WD ² ).

N. dubius Ankylostoma Ascaris nematodes

(mg'kg) (mg / kg)

l-methyl-2- [2- (3-methyl-2-thienyl) vinyl] -

l ² -tetrahydropyrimidine · HCl
l-methyl-2- [2- (3-methyl-2-thienyl) vinyl] -

l ² -tetrahydropyrimidine

1-Methyl-2- [2- (2-thienyl) vinyl] ^{-1 2} -tetrahydropyrimidine · HCl

1 -Methyl-2- [2- (2-thienyl) vinyl] -1 ^{2 -tetrahydropyrimidine}

100 2

100 6

1.25

0.6

2.5

5.95

14.5

MTD = average dose that is toxic to a given number of test animals. WD = Average Effective Dose.

lo 20

The invention is illustrated in the following examples.

example 1
a) 3- (3-Methyl-2-thienyl) acrylonitrile

A solution of 138.7 g (1.10 mol) of 3-methylthiophene-2-carboxaldehyde, 85.0 g (1.0 mol) of cyanoacetic acid, 3 g of ammonium acetate, 110 ecm of pyridine and 200 ecm of toluene was heated under reflux in an apparatus , to which a Dean-Stark water catcher was attached. Heating was continued for 48 hours during which time the solution became very dark. After cooling, the solvents were evaporated under reduced pressure. The less volatile residue was fractionally distilled over a column with Berl saddles as packing, a product being obtained which was initially a colorless oil. B.p. 76 ° C at 0.1 to 0.05 mm; nl ° 1.6330.

b) 1-methyl-2- [2- (3-methyl-2-thienyl) vinyl] -, l ² -tetrahydropyrimidine citrate

Method a

25.1 g 3-methyl-2-thienylacrylamid and 18.7 g of 1,3-propane sultone were heated to 130 to 140 ⁰ C with rapid stirring. After half an hour the reaction mixture solidified to a hard mass. The mixture was heated for an additional half hour, cooled, crushed to a fine powder, and then triturated with acetone and filtered. The imino ether was obtained as a pale yellow solid. The crude imino ether was then used directly for the next step without further purification. 3.5 g of the imino ether and 1.05 g of N-methyltrimethylene diamine were refluxed together in 50 ecm of dry ethanol IV for ₂ hours, the solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was treated with animal charcoal and filtered. The filtrate was made alkaline with 5N NaOH and extracted with chloroform. The organic phase was washed with saturated sodium chloride solution, dried over sodium sulfate and evaporated to dryness. The residue was dissolved in isopropanol and acidified with citric acid. The salt thus obtained was precipitated by adding ether. After three recrystallizations from methanol, the product was obtained as a pale yellow solid.

Method B.

10.8 g of methyl - β - (3 - methyl - 2 - thienyl) - acrylimidate hydrochloride (prepared from the 3- (3-methyl-2-thienyl) acrylonitrile according to a) and methanol, the mixture being heated to -10 ° C was cooled during the saturation with hydrogen chloride) were dissolved in 40 ecm of methanol and added to a solution of 44 g of N-methyltrimethylenediamine in 60 ecm of methanol at 5 to 10 ° C. The mixture was allowed to warm to room temperature, refluxed for 3 hours and then evaporated to dryness. The residue was taken up in 300 ecm of water and then poured into an ice-cooled mixture of 75 cm ^{3 of} 2N sodium hydroxide and 75 cm ^{3 of} methylene chloride with stirring. The organic phase was separated off immediately, dried with sodium sulfate and evaporated.

The free base thus obtained was dissolved in methanol and with a solution of 8.6 g of citric acid in Treated methanol. The citric acid salt was precipitated by the addition of ether and by recrystallization purified from methanol.

The free base in methanol solution gave the hydrochloride on treatment with methanolic hydrogen chloride. Melting point 239 to 241 ⁰ C.

The above citrate was added to a cooled 50% aqueous solution of sodium hydroxide with stirring (in a molar ratio of 1: 1) and 3 volumes of ether. After some Minutes had been stirred, the ether layer was separated and the aqueous phase again with ether extracted. The ether layers were combined, dried over anhydrous magnesium sulfate and washed with Animal charcoal decolorized. After removing the ether, the base was obtained. The free base was in ethanol added, stirred, and an ethanolic solution of tartaric acid (molar ratio 1: 1) was slowly added. The trans-tartrate crystallized and was filtered off. It was decolorized by dissolving in methanol Purified and diluted with 2.5 volumes of ethanol. Concentrating the clear solution on a small volume gave the pure crystalline trans-tartrate.

A solution of 3.0 g of trans-l-methyl-2- [2- (3 - methyl - 2 - thienyl) - vinyl -Λ ² - tetrahydropyrimidine tartrate in 300 cm ^{3 of} methanol was stirred and under nitrogen with a 550 watt High pressure quartz lamp irradiated for 15 hours. Evaporation of the solution under reduced pressure gave the cis isomer. The purification was carried out as described above for the trans isomer.

Example 2

1-methyl-2- [2- (3-methyl-2-thienyl) vinyl] - / 1 ² -tetrahydropyrimidine hydrochloride

A mixture of 12.6 g (0.10 mol) 3-methyl-thiophene-2-carboxaldehyde, 11.2 g (0.10 mol) 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine, 1.5 ecm piperidine and 25 ecm benzene were in heated to reflux in an apparatus fitted with a Dean-Stark device. The mixture was concentrated in vacuo to remove benzene and piperidine. The residue was taken up in 150 ecm of ln hydrochloric acid and the solution washed with ether. The acidic aqueous solution was then extracted with chloroform, which Removed chloroform solution and dried over anhydrous sodium sulfate. After evaporation of the chloroform the product was obtained as a yellow solid which was recrystallized twice from chloroform / benzene would. Melting point: 239 to 241 ° C.

Analysis for C ₁₂ H ₁₇ N ₂ SCl:

Calculated ... C 56.12, H 6.67, N 10.91%;
found .... C 55.58, H 6.80, N 11.01%.

609 637/40

Claims (1)

Patent claims: 1. 1-methyl-2- [2- (3-methyl-2-thienyi) vinyl] - tetrahydropyrimidine of the formula I. The invention relates to 1-methyl-2- [2- (3-methyl-2-thienyU-vinyl] -I ² -ietrahydropyrimidine of the formula I) N- CH = CH- <f